-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease is the main cause of dementia worldwide, and there is currently no effective treatment
.
The obvious genetic, pathological, and clinical heterogeneity among AD patients has brought challenges to traditional drug development.
APOE4 genotype is the largest genetic risk factor for late-onset AD.
Compared with APOE3 genotype, heterozygous carriers (approximately 25% of the population) are 3-4 times more likely to develop AD, and homozygous carriers (approximately 2%) risk is 12-14 times
.
Data show that APOE3 and APOE4 play different roles in the pathogenesis of AD, and AD patients and different APOE genotypes respond differently to drug treatment
Precise
Recently, researchers conducted computational drug reuse screening to find drugs for the treatment of lipoprotein E4 (APOE4)-related AD
.
The researchers first established APOE genotype-dependent AD transcriptome characteristics by analyzing public human brain databases
Computational drug reuse screening Computational drug reuse screening
In two independent EHR databases, bumetanide exposure was associated with a significant reduction in the prevalence of AD in individuals over 65 years of age
.
.
In two independent EHR databases, bumetanide exposure was associated with a significant reduction in the prevalence of AD in individuals over 65 years of age
Bumetanide was determined to be the top drug for the treatment of APOE4-related AD.
In humans, bumetanide exposure is associated with a significant reduction in the prevalence of AD in individuals over 65 years old in two electronic health record databases, indicating the effectiveness of bumetanide in preventing AD.
Original source:
Original source:Alice Taubes et al.
Alice Taubes et al.
Leave a message here
